2/24
04:05 pm
akts
Aktis Oncology to Present at Upcoming March Investor Conferences
Low
Report
Aktis Oncology to Present at Upcoming March Investor Conferences
2/24
08:00 am
akts
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
High
Report
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
2/3
07:00 am
akts
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
2/3
07:00 am
akts
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $31.00 price target on the stock.
Medium
Report
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $31.00 price target on the stock.
2/3
07:00 am
akts
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $34.00 price target on the stock.
Medium
Report
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $34.00 price target on the stock.
2/3
07:00 am
akts
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.
Medium
Report
Aktis Oncology (NASDAQ:AKTS) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.
1/17
01:11 am
akts
Medium
Report
1/13
06:30 am
akts
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares